Chemomab Therapeutics Ltd reports results for the quarter ended in March - Earnings Summary

Chemomab Therapeutics

11/05/2023 13:00

* Chemomab Therapeutics Ltd  CMMB.OQ  reported a quarterly
adjusted loss of 80 cents​​ per share for the quarter ended in
March. The mean expectation of two analysts for the quarter was
for a loss of 4 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Chemomab Therapeutics Ltd's reported EPS for the quarter
was a
loss of 80 cents​.
    * The mean earnings estimate of analysts had risen by
about 95.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Chemomab Therapeutics Ltd shares had risen by 3.1% this
quarter and lost 48.8% so far this year.
    * The company reported a quarterly loss of $8.75 million.
    * Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $12.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 12:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.03          -0.80          Missed
 Dec. 31 2022      -0.04          -0.04          Met
 Sep. 30 2022      -0.33          -0.03          Beat
 Jun. 30 2022      -0.25          -0.54          Missed